Webcast to be held on: May 26, 2023 at 08:00 EST/14:00 CET Stockholm, May 17, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, will hold a webcast including a Q&A session to present interim results from the phase 2a trial […]
Stockholm, May 12, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the Annual General Meeting’s election of two very experienced board members, Dr Elisabeth Björk and Dr Michael Buschle. Read more…
Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction. Endothelial dysfunction is a key driver of organ damage associated with […]
